Intrexon | XON - Cost Of Sales


Intrexon reported $1.01M in Cost of Sales for its fiscal quarter ending in June of 2024.





Cost Of Sales Change Date
Agenus USD 642K 399K Sep/2025
Alaunos Therapeutics USD 0 18K Sep/2024
Amgen USD 1.87B 271M Jun/2026
Anika Therapeutics USD 11.44M 797K Dec/2025
AstraZeneca USD 2.52B 2.73B Jun/2026
Bristol-Myers Squibb USD 7.89B 4.03B Jun/2026
Gilead Sciences USD 1000M 445M Jun/2026
GlaxoSmithKline GBP 2.07B 192M Jun/2026
Heron Therapeutics USD 11.12M 795K Dec/2025
Incyte USD 104.96M 457K Jun/2026
Intrexon USD 1.01M 344K Jun/2024
Karyopharm Therapeutics USD 1.34M 139K Mar/2026
Ligand Pharmaceuticals USD 11.31M 59K Jun/2026
MacroGenics USD 9.53M 585K Mar/2026
MannKind USD 34.21M 5.38M Jun/2026
Merck USD 3.14B 200M Jun/2026
Novartis USD 3.71B 251M Jun/2026
Rigel Pharmaceuticals USD 8.03M 5.22M Sep/2024
Roche Holding CHF 7.85B 630M Jun/2026
Sangamo BioSciences 2.42M 1.11M Jun/2024
Thermo Fisher Scientific USD 7.54B 577M Jun/2026
Veracyte USD 42.19M 3.7M Jun/2026
Xencor USD 61.66M 50.95M Jun/2025